Viragen Will Produce in Sweden
Plantation - US-based Viragen Inc. confirmed in mid-July that its Swedish manufacturing facility in Ersboda is on schedule to commence with the production of Multiferon™ in September. The company has been upgrading and expanding its production capabilities as a result of a more aggressive business direction for its natural human alpha interferon drug. Viragen previously reported that it expects to report data later this year from studies evaluating Multiferon for the treatment of malignant melanoma. “The combined manufacturing capabilities of our existing facility in Umeå with our new facility in Ersboda will provide us with the compliance and capacity necessary to focus on our goal to make Multiferon the world's most prescribed natural human alpha interferon,” stated Viragen's CEO Charles Rice. The construction of the Ersboda facility was completed earlier this year and is currently undergoing validation required by the Swedish regulatory authorities.